Back to search results

A Study of ABBV-313 in Healthy Adults

This study is looking for healthy adult volunteers to help us understand a new investigational drug called ABBV-313. We want to learn about its safety, how well your body tolerates it, and how your body processes it. Some participants will receive ABBV-313 as an injection or infusion, while others will receive a placebo (an inactive substance that looks like the study drug). We'll be checking for any side effects and measuring how much ABBV-313 is in your blood over time. You can join if you are between 18 and 55 years old, in good general health, and have a BMI (Body Mass Index) between 18.0 and 29.9. The study plans to enroll 64 participants, but its current recruitment status is unclear.

Study design
This interventional study plans to enroll 64 healthy adult participants. Some will receive ABBV-313 and others will receive a placebo, either as an injection or an infusion.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for safety and drug levels for up to approximately 329 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07673120

A Study to Assess Safety, Tolerability, and How Single and Multiple Injections or Infusions of ABBV-313 Affects the Body of Adult Participants

Recruiting
PHASE1Ages 18–55InterventionalBasic science
AbbVie
~64 participants
Updated 2026-07-24 on ClinicalTrials.gov
What's tested:ABBV-313Placebo

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Participants with Adverse Events (AEs)
Measured over Up to Approximately Day 329
+5 more outcomes measured

Conditions

Healthy Volunteers

Explore related trials

Healthy Volunteers

NCT07673120

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Acpru /Id# 283495

    Grayslake, Illinoisno site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • ABBVIE INC. · STUDY_DIRECTOR · AbbVie

Who to contact

ABBVIE CALL CENTER
[email protected]
844-663-3742
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

BMI is \>= 18.0 to \<= 29.9 kg/m2 after rounding to the tenths decimal at Screening. BMI is calculated as weight in kg divided by the square of height measured in meters.
A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead ECG.

Exclusion

History of any clinically significant sensitivity or allergy to any medication or food.
History of any clinically significant illness/infection/major febrile illness, hospitalization, or any surgical procedure within 30 days prior to the first dose of study treatment.
Participant has prior exposure to ABBV-313 within the past 300 days.

What this trial measures

  • Number of Participants with Adverse Events (AEs)Up to Approximately Day 329

    An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

  • Maximum Observed Plasma Concentration (Cmax) of ABBV-313Up to Approximately Day 329

    Cmax of ABBV-313.

  • Time to Cmax (Tmax) of ABBV-313Up to Approximately Day 329

    Tmax of ABBV-313.

  • Terminal Phase Elimination Rate Constant (Beta) of ABBV-313Up to Approximately Day 329

    Beta of ABBV-313.

  • Terminal Phase Elimination Half-Life (t1/2) of ABBV-313Up to Approximately Day 329

    t1/2 of ABBV-313.

  • Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to the Time of the Last Measurable Concentration (AUCt) of ABBV-313Up to Approximately Day 329

    AUCt of ABBV-313.